摘要
目的探讨不稳定型心绞痛患者应用尼可地尔辅助治疗的预后疗效及安全性评价。方法将2015年1月～2016年12月本院收治的140例不稳定型心绞痛患者纳入本次研究,根据入院顺序先后随机均分为研究组和对照组,各70例。对照组患者予以钙离子拮抗剂、硝酸异山梨酯、他汀类、氯吡格雷及阿司匹林等药物常规治疗;研究组在对照组的基础上加用尼可地尔(5mg,tid)。治疗后,将两组患者预后疗效、心绞痛发生情况、主要心血管不良事件进行统计学分析。结果治疗后,研究组治疗有效率明显高于对照组,差异有统计学意义(P <0.01);治疗前,两组患者心绞痛发生次数组间比较无显著差异(P> 0.05);治疗后,两组患者心绞痛发生次数分别较各自治疗前心绞痛发生次数明显降低,且研究组低于对照组,差异有统计学意义(P <0.01);治疗期间,研究组主要心血管不良事件发生率与对照组患者患者比较无显著差异(P> 0.05)。结论不稳定型心绞痛患者应用尼可地尔辅助治疗可明显缓解疾病相关症状,具有较高的治疗有效性及安全性。
Objective To evaluate the efficacy and safety of nicodil adjuvant therapy in patients with unstable angina pectoris. Methods 140 patients with unstable angina pectoris admitted to our hospital from January 2015 to December 2016 were included in this study. According to the order of admission, they were randomly divided into research group and control group, 70 cases for each group. Patients in the control group were routinely treated with calcium antagonists, isosorbide nitrate, statins, clopidogrel and aspirin. The research group was treated with nichodil (5mg, tid) on the basis of treatments in the control group. The prognosis, angina, and major cardiovascular adverse events of the two groups were statistically analyzed after treatment. Results After treatment, the effective rate in the study group was significantly higher than that in the control group (P < 0.01). Before treatment, there was no significant difference in the incidence of angina pectoris between the two groups (P > 0.05). After treatment, the incidence of angina in the two groups was significantly lower than that before treatment, and the incidence in the research group was lower than that in the control group, the difference was statistically significant (P < 0.01). During the treatment period, there was no significant difference in the incidence of major adverse cardiovascular events between the research group and the control group (P > 0.05). Conclusion Nicodil adjuvant therapy is effective and safe in the treatment of unstable angina.
作者
孟宪磊
任建明
刘振华
MENG Xian-lei;REN Jian-ming;LIU Zhen-hua(the second department of cardiology, the first people's hospital of luoyang, Luoyang, Henan, 471000, China)
出处
《临床研究》
2019年第5期34-35,共2页
Clinical Research
